Metrics as of 10/13/2026, 06:54 PM (Berlin time), refresh in progress.
Atrium Therapeutics Stock
Atrium Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Kathleen Gallagher
- Employees
- 511
- Market cap
- $135 M
- IPO
- 27/02/2026
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for…
Atrium Therapeutics stock: price history
1D
-3.7%
1W
-1.0%
1M
-23.6%
6M
-43.6%
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~41% weaker price swings than usual
Ask the agents about Atrium Therapeutics
Analyst assessment of Atrium Therapeutics
PRICE TARGET LOW
US$25.00
CONSENSUS
US$25.00
MEDIAN
US$25.00
PRICE TARGET HIGH
US$25.00
0
STRONG BUY
8
BUY
8
HOLD
0
SELL
0
STRONG SELL
16
TOTAL · Buy
As of: 14/08/2026
Atrium Therapeutics stock metrics
P/E
-2.05
P/B
0.63
EV/EBITDA
-0.67
RETURN ON EQUITY
-9.4%
NET MARGIN
-672.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.9%
FLOAT SHARES
15,720,941
AVG. DAILY VOLUME (30D)
385,782
Insider transactions (SEC)
Hoyos Rocio Martin
Winslow Brendan R.
Gallagher Kathleen P.
Kenney Stephanie
Boyce Sarah
Institutional holders
Comparable stocks
Frequently asked questions about Atrium Therapeutics stock
What does Atrium Therapeutics do?
Atrium Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Kathleen Gallagher, the company employs around 511 people.
The IPO was on 27/02/2026; the stock trades on NASDAQ under the ticker RNA.
What do analysts say about Atrium Therapeutics stock?
16 analysts rate the stock, the consensus is Buy (as of 14/08/2026).
The average price target is US$25.00, ranging from US$25.00 to US$25.00, with a median of US$25.00.
This is an external assessment, not a statement by Market Jury.
When does Atrium Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -41% stronger than usual.
Does Atrium Therapeutics pay a dividend?
No, Atrium Therapeutics currently does not pay a dividend.
Which stocks are comparable to Atrium Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Atrium Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Atrium Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.